<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bosutinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bosutinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bosutinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="86615" href="/d/html/86615.html" rel="external">see "Bosutinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F15367319"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bosulif</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871497"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Bosulif</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F14965011"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, BCR-ABL Tyrosine Kinase Inhibitor;</li>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F15034523"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Bosutinib is associated with a moderate or high emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>); nausea and vomiting may be managed with antiemetics and fluid replacement.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="00aca3dd-d6df-4728-b215-b4455bd86b37">Chronic myeloid leukemia, Philadelphia chromosome-positive, chronic phase, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia, Philadelphia chromosome-positive, chronic phase, newly diagnosed:</b>
<b>Oral:</b> 400 mg once daily; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29091516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29091516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose escalation</i>
<i>:</i> In clinical studies, dose escalation in increments of 100 mg once daily (to a maximum of 600 mg once daily) was allowed in patients who did not achieve or maintain a hematologic, cytogenetic, or molecular response (in the absence of ≥ grade 3 adverse reactions).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa62d30f-abad-433c-8d63-b35d4acf52fe">Chronic myeloid leukemia, Philadelphia chromosome-positive, chronic, accelerated, or blast phase, resistant or intolerant to prior therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia, Philadelphia chromosome-positive, chronic, accelerated, or blast phase, resistant or intolerant to prior therapy:</b>
<b>Oral:</b> 500 mg once daily; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21865346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21865346'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose escalation</i>
<i>:</i> In clinical studies, dose escalation in increments of 100 mg once daily (to a maximum of 600 mg once daily) was allowed in patients who did not achieve or maintain a hematologic, cytogenetic, or molecular response (in the absence of ≥ grade 3 adverse reactions).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> If a dose is missed beyond 12 hours, skip the dose and resume the usual dose the following day. If entire dose/contents of capsules prepared in applesauce or yogurt is not consumed, do not administer an additional dose; wait until the next day to resume dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991351"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Kidney function estimated using the Cockcroft-Gault equation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic myeloid leukemia, chronic phase, newly diagnosed:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;50 to 80 mL/minute: There are no dosage adjustments provided in manufacturer's labeling; however, no clinically significant effect on bosutinib pharmacokinetics was observed in mild kidney dysfunction.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 50 mL/minute: Reduce dose to 300 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Reduce dose to 200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic myeloid leukemia, chronic, accelerated, or blast phase, resistant or intolerant to prior therapy:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;50 to 80 mL/minute: There are no dosage adjustments provided in manufacturer's labeling; however, no clinically significant effect on bosutinib pharmacokinetics was observed in mild kidney dysfunction.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 50 mL/minute: Reduce dose to 400 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Reduce dose to 300 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney toxicity during treatment:</b> If declining kidney function occurs, reduce dose per adjustment recommendations for toxicity (withhold bosutinib until resolved, then consider resuming with the daily dose reduced by 100 mg; if clinically appropriate, may re-escalate dose to the starting dose).</p></div>
<div class="block doha drugH1Div" id="F50988349"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia, newly diagnosed (chronic phase) or resistant/intolerant to prior therapy (chronic, accelerated, or blast phase):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Child-Turcotte-Pugh class A, B, or C: Reduce initial dose to 200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:6em;">ALT or AST &gt;5 times ULN: Withhold bosutinib until recovery to ≤2.5 times ULN and resume at 400 mg once daily thereafter. If recovery to ≤2.5 times ULN takes &gt;4 weeks: Discontinue bosutinib.</p>
<p style="text-indent:-2em;margin-left:6em;">ALT or AST ≥3 times ULN in conjunction with bilirubin elevation &gt;2 times ULN and alkaline phosphatase &lt;2 times ULN: Discontinue bosutinib.</p></div>
<div class="block dot drugH1Div" id="F15034525"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia, newly diagnosed (chronic phase) or resistant/intolerant to prior therapy (chronic, accelerated, or blast phase):</b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Bosutinib Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Bosutinib dosage modification</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> ASCO (Armenian 2017); ESC (Lyon 2022).</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">Hematologic toxicity</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neutropenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ANC &lt;1,000/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold bosutinib until ANC ≥1,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">
<i>ANC recovery to </i>
<i>≥1,000/mm<sup>3 </sup>within 2 weeks following interruption:</i> Resume bosutinib at same dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>ANC recovery to </i>
<i>≥1,000/mm<sup>3 </sup>after more than 2 weeks following interruption:</i> Upon recovery, resume bosutinib with the daily dose reduced by 100 mg.</p>
<p style="text-indent:0em;text-align:left;">
<i>Recurrent neutropenia (ANC &lt;1,000/mm<sup>3</sup>):</i> Withhold bosutinib until ANC ≥1,000/mm<sup>3</sup>. Upon recovery, resume bosutinib with the daily dose reduced by an additional 100 mg.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Thrombocytopenia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Platelets &lt;50,000/mm<sup>3</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold bosutinib until platelets ≥50,000/mm<sup>3</sup>.</p>
<p style="text-indent:0em;text-align:left;">
<i>Platelet recovery to ≥50,000/mm<sup>3 </sup>within 2 weeks following interruption:</i> Resume bosutinib at same dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>Platelet recovery to ≥50,000/mm<sup>3 </sup> after more than 2 weeks following interruption:</i> Upon recovery, resume bosutinib with the daily dose reduced by 100 mg.</p>
<p style="text-indent:0em;text-align:left;">
<i>Recurrent thrombocytopenia (platelets &lt;50,000/mm<sup>3</sup>):</i> Withhold bosutinib until platelets ≥50,000/mm<sup>3</sup>. Upon recovery, resume bosutinib with the daily dose reduced by an additional 100 mg.</p></td></tr>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">Nonhematologic toxicity</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Diarrhea</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3 to 4 (≥7 stools/day increase over baseline/pretreatment)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Manage with antidiarrheals and fluid replacement as clinically necessary.</p>
<p style="text-indent:0em;text-align:left;">Withhold bosutinib until recovery to ≤ grade 1; may resume at 400 mg once daily.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Any (clinically significant)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If indicated, initiate appropriate antihypertensive therapy to reduce the risk for cardiovascular complications.<sup>a</sup></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Other treatment-related adverse events</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Moderate to severe</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold bosutinib until resolved; consider resuming with the daily dose reduced by 100 mg; may re-escalate dose to the starting dose if clinically appropriate.</p>
<p style="text-indent:0em;text-align:left;">Doses &lt;300 mg daily have been used; however, efficacy has not been established.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F15034524"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F15236368"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (8% to 12%), edema (15% to 19%), hypertension (8% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (7% to 12%), skin rash (children, adolescents, and adults: 40% to 49%, including drug reaction with eosinophilia and systemic symptoms, exfoliative dermatitis, fixed drug eruption, maculopapular rash)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum calcium (children and adolescents: 31%; adults: 45% to 55%), decreased serum phosphate (33% to 54%), decreased serum potassium (22% to 29%), decreased serum sodium (18% to 27%), hypermagnesemia (18% to 27%), increased serum glucose (children and adolescents: 41%; adults: 39% to 57%), increased serum potassium (19% to 25%), increased serum sodium (11% to 23%), increased uric acid (43% to 49%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children and adolescents: 73%; adults: 36% to 49%), constipation (children, adolescents, and adults: 13% to 20%), decreased appetite (children and adolescents: 27%; adults: 11% to 14%), diarrhea (children, adolescents, and adults: 75% to 85%, grades 3/4: 4% to 12%), increased serum amylase (children, adolescents, and adults: 27% to 32%), increased serum lipase (19% to 53%), nausea (children, adolescents, and adults: 37% to 49%, grades 3/4: 1% to 2%), vomiting (children and adolescents: 55%, grades 3/4: 6%; adults: 21% to 43%, grades 3/4: 1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decrease in absolute neutrophil count (42% to 66%, grades 3/4: 9% to 39%), decreased hemoglobin (children and adolescents: 31%, grades 3/4: 8%; adults: 89% to 97%, grades 3/4: 9% to 38%), decreased neutrophils (children and adolescents: 31%, grades 3/4: 12%), decreased platelet count (children and adolescents: 49%, grades 3/4: 18%; adults: 66% to 80%, grades 3/4: 14% to 57%), decreased white blood cell count (children, adolescents, and adults: 50% to 57%, grades 3/4: 4% to 27%), lymphocytopenia (children and adolescents: 29%, grades 3/4: 2%; adults: 79% to 84%, grades 3/4: 12% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic impairment (children, adolescents, and adults: 21% to 45%), increased serum alanine aminotransferase (children, adolescents, and adults: 39% to 68%), increased serum alkaline phosphatase (39% to 41%), increased serum aspartate aminotransferase (children, adolescents, and adults: 37% to 56%), increased serum bilirubin (16% to 22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (3% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (11% to 14%), fatigue (children, adolescents, and adults: 27% to 37%, including asthenia), headache (children and adolescents: 35%; adults: 18% to 22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (15% to 19%), back pain (8% to 14%), increased creatine phosphokinase in blood specimen (children and adolescents: 25%; adults: 36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (children, adolescents, and adults: 87% to 95%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (11% to 24%), dyspnea (11% to 20%), pleural effusion (9% to 14%), pneumonia (10% to 18%), respiratory tract infection (children and adolescents: 12%; adults: 17% to 27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children, adolescents, and adults: 17% to 37%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (children and adolescents: 2%), coronary artery disease (serious: 3% to 4%), heart failure (2% to 5%), ischemic heart disease (5%), pericardial effusion (children and adolescents: grades 1/2: 2%; adults: grades 3/4: ≤4%), peripheral edema (children and adolescents: 2%), prolonged QT interval on ECG, right bundle branch block (children and adolescents: 2%), sinus tachycardia (children and adolescents: 2%), tachycardia (children and adolescents: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, fluid retention (grades 3/4: 1% to 6%), hypothyroidism</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, gastritis, gastroenteritis (serious: 2%), gastrointestinal hemorrhage (including anal hemorrhage, rectal hemorrhage), pancreatitis (including acute pancreatitis, chronic pancreatitis, edematous pancreatitis, increased pancreatic enzymes)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (children and adolescents: 2%), hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Pain</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, kidney failure, kidney impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, pulmonary hypertension</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pericarditis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperthyroidism</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute pulmonary edema, interstitial lung disease, respiratory failure</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Left ventricular dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased estimated GFR (eGFR)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome (Avila-Castano 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombotic microangiopathy</p></div>
<div class="block coi drugH1Div" id="F15034466"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to bosutinib or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): History of long QT syndrome or with persistent QT interval &gt;480 milliseconds; uncorrected hypokalemia or hypomagnesemia; hepatic impairment.</p></div>
<div class="block war drugH1Div" id="F15034474"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Anemia, neutropenia, and thrombocytopenia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular toxicity: Bosutinib may cause cardiovascular toxicity, such as cardiac failure, left ventricular dysfunction, and cardiac ischemic events. Cardiac failure events occurred more commonly in previously treated patients versus those with newly diagnosed chronic myeloid leukemia (CML); events were also more frequent in patients with advanced age or risk factors (including a past medical history of cardiac failure). Cardiac ischemic events occurred more frequently in patients with coronary artery disease risk factors, including a history of diabetes, BMI &gt;30, hypertension, and vascular disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid retention/edema: Fluid retention, manifesting as pericardial effusion, pleural effusion, pulmonary edema and/or peripheral edema may occur; may be severe.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Diarrhea, nausea, vomiting, and abdominal pain may occur. For patients experiencing diarrhea (all grades), the median time to onset in patients with CML resistant or intolerant to prior therapy was 2 days; median duration (per event) was 2 days and the median number of diarrhea episodes per patient was 3 (range: 1 to 268). Similarly, the median time to onset for diarrhea (all grades) in patients with newly diagnosed CML was 4 days; the median duration per events was 3 days. GI hemorrhages have also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Serum transaminase (ALT and/or AST) elevations have been reported. In patients with transaminase elevation, ~70% to 80% developed the transaminase elevation within the first 3 months of therapy. In a clinical study in patients with newly diagnosed chronic phase CML, the median time to onset of elevated ALT and AST was 29 and 56 days, respectively; the median duration was 19 and 15 days, respectively. In patients with CML resistant or intolerant to prior therapy, the mediation time to onset of ALT and AST elevation was 22 and 29 days, respectively, and the median duration (for each) was 21 days. Rare cases of drug-induced liver injury (without alternative etiologies) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions have been reported, including anaphylaxis and anaphylactic shock (rare).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney toxicity: Declines in GFR throughout bosutinib treatment have been observed in clinical studies.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: QTcF &gt;500 milliseconds was observed rarely in clinical trials (Cortes 2012); patients with significant or uncontrolled cardiovascular disease (including prolonged QT interval at baseline) were not studied.</p></div>
<div class="block foc drugH1Div" id="F15367320"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bosulif: 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bosulif: 100 mg, 400 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F15034461"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16570453"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Bosulif Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $200.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $200.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Bosulif Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $200.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $802.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $802.68</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871498"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bosulif: 100 mg, 500 mg</p></div>
<div class="block adm drugH1Div" id="F15034528"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib is associated with a moderate or high emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>); nausea and vomiting may be managed with antiemetics and hydration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Administer with food. Swallow tablet whole; do not cut, crush, break, or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Administer with food; may be swallowed whole. For patients that are unable to swallow the whole capsule(s), the capsule may be opened, and the contents mixed with room temperature applesauce or yogurt (not a replacement for a full meal). Remove the required number of capsules from the container to prepare the dose; carefully open each capsule and add the entire content into the appropriate volume of applesauce or yogurt (which has been placed in a clean container) and mix. Immediately consume the full volume of the mixture; do not chew. Do not store mixture for later use; do not administer an additional dose if entire contents are not consumed.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Recommended Preparation for Bosutinib Capsules Mixed with Applesauce or Yogurt</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Bosutinib dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Volume of applesauce or yogurt</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">100 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mL (2 teaspoons)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">200 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mL (4 teaspoons)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">300 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mL (6 teaspoons)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">400 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">35 mL (7 teaspoons)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">500 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">45 mL (9 teaspoons)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">600 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50 mL (10 teaspoons)</p></td></tr></tbody></table></div>
<div class="block hazard drugH1Div" id="F49104434"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F14965013"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic myeloid leukemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of chronic phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in adults and pediatric patients ≥1 year of age who are newly diagnosed or with resistance or intolerance to prior therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of accelerated or blast phase Ph+ CML in adults with resistance or intolerance to prior therapy.</p></div>
<div class="block mst drugH1Div" id="F15034460"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bosutinib may be confused with bortezomib, bosentan, brigatinib, dasatinib, imatinib, nilotinib, PONATinib</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medical Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F15255889"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F15255887"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Bosutinib. Management: Administer antacids more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bitter Orange: May increase the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing these oncologic agents several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Bosutinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Bosutinib. Management: Administer histamine H2 receptor antagonists (H2RAs) more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the serum concentration of Bosutinib. Management: Consider alternatives to proton pump inhibitors and potassium-competitive acid blockers, such as short-acting antacids or histamine-2 receptor antagonists. Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Bosutinib may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: May enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomegranate: May increase the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Miscellaneous Oncologic Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Star Fruit: May increase the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Miscellaneous Oncologic Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F15034495"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit juice may increase bosutinib plasma concentration. Management: Avoid grapefruit juice during bosutinib therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib C<sub>max</sub> and AUC increased by 1.8- and 1.7-fold, respectively, when bosutinib tablets were administered with a high-fat meal (800 to 1,000 calories with 150 protein calories, 250 carbohydrate calories, and 500 to 600 fat calories), compared to a fasted state. Bosutinib C<sub>max</sub> and AUC increased by 1.6- and 1.5-fold, respectively, when bosutinib capsules were administered with a high-fat meal, compared to a fasted state. Management: Administer with food.</p></div>
<div class="block rep_considerations drugH1Div" id="F49095593"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to initiating therapy in patients who could become pregnant. Patients who could become pregnant should use effective contraception (methods that result in &lt;1% pregnancy rates) during bosutinib treatment and for 2 weeks after the last bosutinib dose.</p>
<p style="text-indent:0em;margin-top:2em;">Changes in menstrual patterns have been reported with tyrosine kinase inhibitor (TKI) therapy (Yu 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action, TKIs have the potential to adversely affect fertility by acting on receptors in the ovaries or testis; primarily when administered prior to puberty in males. Although there are cases showing difficulty conceiving, successful pregnancies have also been reported. Fertility data related to long term TKI use are limited. Recommendations are available for fertility preservation prior to TKI treatment (ASCO [Oktay 2018]; Madabhavi 2019; Rambhatla 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Patients planning to become pregnant but currently receiving a TKI should minimize the risk of first trimester exposure (Rambhatla 2021). Discontinuing TKI therapy for chronic myeloid leukemia can be considered if the patient is eligible for a tumor-free remission, allowing a washout period before attempting to conceive (Baccarani 2019; ELN [Hochhaus 2020]; Madabhavi 2019). Because the time to conception can be highly variable, treatment may also be discontinued at the first positive pregnancy test, prior to organogenesis in select patients (Abruzzese 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following male use of bosutinib prior to conception are limited (Cortes 2020; Szakács 2020).</p></div>
<div class="block pri drugH1Div" id="F15034463"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following use of bosutinib during pregnancy are limited (Assi 2021; Cortes 2020). Based on data from animal reproduction studies and the mechanism of action, in utero exposure to bosutinib may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Treatment of chronic myeloid leukemia in pregnant patients should be individualized based on gestational age, hematologic parameters, and clinical condition at presentation. If pregnancy is detected in the first trimester in patients already on a tyrosine kinase inhibitor (TKI), treatment should be discontinued as soon as pregnancy is confirmed. Treatments other than a TKI are recommended in pregnant patients not eligible for a tumor-free remission. If a TKI is needed, use of agents other than bosutinib may be considered after the first trimester. Close maternal and fetal monitoring is recommended (Abruzzese 2020; BSH [Smith 2020]; ELN [Hochhaus 2020]; Madabhavi 2019).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) approach (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F15034465"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if bosutinib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 2 weeks after the last bosutinib dose. Patients diagnosed with chronic myeloid leukemia requiring a tyrosine kinase inhibitor may consider short-term breastfeeding for the first 2 to 5 days postpartum to provide the benefits of colostrum to the newborn prior to starting or restarting therapy (Abruzzese 2020; Madabhavi 2019).</p></div>
<div class="block mop drugH1Div" id="F15034531"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential (weekly during first month, then monthly thereafter, or as clinically indicated); hepatic enzymes (monthly for first 3 months and as clinically indicated; monitor more frequently with transaminase elevations); kidney function (at baseline and throughout therapy, particularly in patients with preexisting impairment or other risk factors for kidney dysfunction). Verify pregnancy status (prior to treatment initiation in patients who could become pregnant). Monitor for diarrhea episodes; fluid/edema status (eg, weight gain). Monitor for signs/symptoms of cardiac failure and cardiac ischemia. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Additional cardiovascular monitoring:</i> Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; repeat assessment every 3 months for the first year and then every 6 to 12 months thereafter (ASCO [Armenian 2017]; ESC [Lyon 2022]). ECG at baseline. Consider baseline echocardiography in all patients; repeat every 3 months for high- and very high-risk patients (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F15034498"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Bosutinib is a BCR-ABL tyrosine kinase inhibitor (TKI); inhibits BCR-ABL kinase that promotes CML. Also inhibits SRC family (including SRC, LYN, and HCK). Bosutinib has minimal activity against c-KIT and platelet-derived growth factor receptor (PDGFR), which are nonspecific targets associated with toxicity in other TKIs (Cortes 2012). Bosutinib has activity in 16 of 18 imatinib-resistant BCR-ABL mutations, with the exceptions of the T315I and V299L mutants (Cortes 2011).</p></div>
<div class="block phk drugH1Div" id="F15034500"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset:</p>
<p style="text-indent:-2em;margin-left:4em;">Median time to complete hematologic response (in responders): 2 weeks (Cortes 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Median time to major cytogenetic response (in responders): 12.3 weeks (Cortes 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Median time to first complete cytogenic response: 12.9 weeks (Cortes 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Slow (Abbas 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 6,080 ± 1,230 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 94% to plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4, primarily to inactive metabolites oxydechlorinated (M2) bosutinib and <i>N</i>-desmethylated (M5) bosutinib, also to bosutinib <i>N</i>-oxide (M6).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 34% when administered with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 22.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 6 hours (for a single 500 mg dose with food).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~91%); urine (~3%).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance (mean): 189 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F51154132"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: A single 200 mg dose was administered to subjects in a kidney impairment study; the AUC was increased 1.4-fold in patients with moderate impairment (CrCl 30 to 50 mL/minute) and 1.6-fold in patients with severe impairment (CrCl &lt;30 mL/minute), compared to patients with normal kidney function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In a hepatic impairment study (in patients with Child-Pugh classes A, B, and C administered a single 200 mg dose), the C<sub>max</sub> of bosutinib increased 2.4-, 2-, and 1.5- fold, respectively, and the AUC increased 2.3-, 2-, and 1.9-fold, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23671833"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bosulif | Regitrat</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bosulif | Xolyxa</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Xolyxa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bonitar | Bosutris</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Bosulif | Volopem</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Bosulif | Volopem</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Xolyxa</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bosulif</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23053269">
<a name="23053269"></a>Abbas R, Chalon S, Leister C , El Gaaloul M, Sonnichsen D, Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. <i>Cancer Chemother Pharmacol</i>. 2013;71(1):123-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/23053269/pubmed" id="23053269" target="_blank">23053269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21691746">
<a name="21691746"></a>Abbas R, Hug BA, Leister C, et al, “A Phase I Ascending Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Bosutinib (SKI-606) in Healthy Adult Subjects,” <i>Cancer Chemother Pharmacol</i>, 2012, 69(1):221-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/21691746/pubmed" id="21691746" target="_blank">21691746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33194164">
<a name="33194164"></a>Abruzzese E, Mauro M, Apperley J, Chelysheva E. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. <i>Ther Adv Hematol</i>. 2020;11:2040620720966120. doi:10.1177/2040620720966120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/33194164/pubmed" id="33194164" target="_blank">33194164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33283580">
<a name="33283580"></a>Assi R, Kantarjian H, Keating M, et al. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-center experience. <i>Leuk Lymphoma</i>. 2021;62(4):909-917. doi:10.1080/10428194.2020.1849672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/33283580/pubmed" id="33283580" target="_blank">33283580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35449618">
<a name="35449618"></a>Avila-Castano K, Morgenstern-Kaplan D, Carrillo-Martin I, Gonzalez-Estrada A. Bosutinib-induced Stevens-Johnson syndrome and evidence of tolerance to a structurally dissimilar tyrosine kinase inhibitor. <i>Cureus</i>. 2022;14(3):e23288. doi:10.7759/cureus.23288<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/35449618/pubmed" id="35449618" target="_blank">35449618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31869412">
<a name="31869412"></a>Baccarani M, Abruzzese E, Accurso V, et al. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Adv</i>. 2019;3(24):4280-4290. doi:10.1182/bloodadvances.2019000865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/31869412/pubmed" id="31869412" target="_blank">31869412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bosulif.2">
<a name="Bosulif.2"></a>Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bosulif.3">
<a name="Bosulif.3"></a>Bosulif (bosutinib) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33005329">
<a name="33005329"></a>Cortes JE, Gambacorti-Passerini C, Deininger M, Abruzzese E, DeAnnuntis L, Brümmendorf TH. Pregnancy outcomes in patients treated with bosutinib. <i>Int J Hematol Oncol</i>. 2020;9(2):IJH26. doi:10.2217/ijh-2020-0004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/33005329/pubmed" id="33005329" target="_blank">33005329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29091516">
<a name="29091516"></a>Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. <i>J Clin Oncol. </i>2018;36(3):231-237. doi: 10.1200/JCO.2017.74.7162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/29091516/pubmed" id="29091516" target="_blank">29091516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21865346">
<a name="21865346"></a>Cortes JE, Kantarjian HM, Brümmendorf TH, et al, “Safety and Efficacy of Bosutinib (SKI-606) in Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Imatinib,” <i>Blood</i>, 2011, 118(17):4567-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/21865346/pubmed" id="21865346" target="_blank">21865346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22949154">
<a name="22949154"></a>Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. <i>J Clin Oncol</i>. 2012;30(28):3486-3492.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/22949154/pubmed" id="22949154" target="_blank">22949154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24944159">
<a name="24944159"></a>Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. <i>Am J Hematol</i>. 2014;89(10):947-953.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/24944159/pubmed" id="24944159" target="_blank">24944159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32127639">
<a name="32127639"></a>Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. <i>Leukemia</i>. 2020;34(4):966-984. doi:10.1038/s41375-020-0776-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/32127639/pubmed" id="32127639" target="_blank">32127639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22371878">
<a name="22371878"></a>Khoury HJ, Cortes JE, Kantarjian HM, et al, “Bosutinib is Active in Chronic Phase Chronic Myeloid Leukemia After Imatinib and Dasatinib and/or Nilotinib Therapy Failure,” <i>Blood</i>, 2012, 119(15):3403-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/22371878/pubmed" id="22371878" target="_blank">22371878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31584851">
<a name="31584851"></a>Madabhavi I, Sarkar M, Modi M, Kadakol N. Pregnancy outcomes in chronic myeloid leukemia: a single center experience. <i>J Glob Oncol</i>. 2019;5:1-11. doi:10.1200/JGO.18.00211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/31584851/pubmed" id="31584851" target="_blank">31584851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620997">
<a name="29620997"></a>Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/29620997/pubmed" id="29620997" target="_blank">29620997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO guidelines working group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-70. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33826052">
<a name="33826052"></a>Rambhatla A, Strug MR, De Paredes JG, Cordoba Munoz MI, Thakur M. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review. <i>J Assist Reprod Genet</i>. 2021;38(8):1897-1908. doi:10.1007/s10815-021-02181-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/33826052/pubmed" id="33826052" target="_blank">33826052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32734668">
<a name="32734668"></a>Smith G, Apperley J, Milojkovic D, et al; British Society for Haematology. A British Society for Haematology guideline on the diagnosis and management of chronic myeloid leukaemia. <i>Br J Haematol</i>. 2020;191(2):171-193. doi:10.1111/bjh.16971<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/32734668/pubmed" id="32734668" target="_blank">32734668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33270732">
<a name="33270732"></a>Szakács Z, Hegyi PJ, Farkas N, et al. Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a systematic review. <i>PLoS One</i>. 2020;15(12):e0243045. doi:10.1371/journal.pone.0243045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/33270732/pubmed" id="33270732" target="_blank">33270732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31770225">
<a name="31770225"></a>Yu L, Huang X, Gale RP, Wang H, Jiang Q. Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. <i>Medicine (Baltimore)</i>. 2019;98(48):e18079. doi:10.1097/MD.0000000000018079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/31770225/pubmed" id="31770225" target="_blank">31770225</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 86371 Version 238.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
